ReviewFrontiers in immunology2022

Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.

Susanna Esposito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.